Department of Pharmacology, Institute of Biological Sciences, Federal University of Juiz de Fora, Minas Gerais, Brazil.
Department Parasitology, Microbiology and Immunology, Institute of Biological Sciences, Federal University of Juiz de Fora, Minas Gerais, Brazil.
Int J Rheum Dis. 2017 Dec;20(12):1958-1964. doi: 10.1111/1756-185X.12589. Epub 2015 May 8.
Osteoarthritis (OA) is a major cause of morbidity and incapacity in the elderly. This study evaluates serum levels of the chemokines CCL2, CXCL8, CXCL9, and CXCL10 in 16 patients with primary OA of the knees, and investigates how treatment with hydroxychloroquine (HCQ) for 4 months affects these chemokine levels.
Thirteen elderly patients received a placebo. Healthy control groups consisted of 10 elderly individuals (age > 60 years) with no clinical or radiological evidence of OA (CT-O), and 10 young adult individuals, (CT-Y group, age < 40 years).
The CT-Y group presented lower levels of all chemokines studied, in comparison to the other groups. HCQ treatment did not alter the serum levels of CCL2 (P = 0.80), CXCL8 (P = 0.76), CXCL9 (P = 0.95) and CXCL10 (P = 0.74) in OA patients.
Hydroxychloroquine treatment did not alter the serum levels of CCL2, CXCL8, CXCL9 or CXCL10 in patients with OA of the knees, although increased serum levels correlated with aging for all subjects, including controls.
骨关节炎（OA）是老年人发病率和失能的主要原因。本研究评估了 16 例膝关节原发性 OA 患者血清中趋化因子 CCL2、CXCL8、CXCL9 和 CXCL10 的水平，并研究了羟氯喹（HCQ）治疗 4 个月对这些趋化因子水平的影响。
13 名老年患者接受安慰剂治疗。健康对照组包括 10 名无临床或影像学证据的老年 OA 患者（CT-O）（年龄>60 岁）和 10 名年轻成年患者（CT-Y 组，年龄<40 岁）。
CT-Y 组所有研究趋化因子的水平均低于其他组。HCQ 治疗未改变 OA 患者血清中 CCL2（P=0.80）、CXCL8（P=0.76）、CXCL9（P=0.95）和 CXCL10（P=0.74）的水平。
尽管包括对照组在内的所有受试者的血清水平均与年龄相关，但羟氯喹治疗并未改变膝关节 OA 患者血清中 CCL2、CXCL8、CXCL9 或 CXCL10 的水平。
